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Introduction
Increased B cell activating factor (BAFF) in the serum
of juvenile-onset systemic lupus erythematosus (JSLE)
patients is thought to be key to the survival of auto-
reactive B cells. BAFF signals through three receptors,
BAFF-R, BCMA and TACI, activating the NF-B path-
way. Belimumab is a human monoclonal antibody
against BAFF that has recently become the first drug
licensed for the treatment of SLE in 50 years. In order
to investigate the potential effect of BAFF inhibition
on the wider immune system, receptor expression was
investigated in another SLE pathogenic cell, the
T lymphocyte.
Objectives
To determine T cell expression of the BAFF-R and BCMA
receptors and the effect of BAFF on cell survival in JSLE
patients compared to healthy paediatric controls.
Methods
Lymphocytes were isolated from JSLE patients and
healthy paediatric controls. Cells were dual immunos-
tained with flurochrome conjugated monoclonal anti-
bodies for BAFF receptors, BAFF-R or BCMA (FITC
labelled) as well as the T cell marker CD3 (PECy5
labelled) allowing detection of T cells expressing the
receptor to be identified by flow cytometry (n=8).
Survival of T cells was assessed by quantifying the
degree of apoptosis taking place using an Annexin V
stain after 4 hours incubation with recombinant human
BAFF (rhBAFF); receptor expression was analysed as
stated previously (n=5). Results expressed as: mean
+/-SEM. Statistical significance was taken when p values
were <0.05.
Results
The total lymphocyte population was found to express
both BAFF-R and BCMA receptors similarly in JSLE
patients (BAFF-R 14.8%+/-3.15; BCMA 4.98+/-0.86) and
controls (BAFFR 8.2%+/-1.6; BCMA 6.07+/-0.87). T cells
also displayed similar expression (JSLE: BAFF-R 3.37%
+/-0.42; BCMA: 1.91+/-0.31; Controls: BAFF-R, 3.27%
+/-0.82; BCMA, 2.34+/-0.96) with BAFF-R receptor
expressed more frequently than BCMA in both cohorts.
Importantly, incubation with rhBAFF led to an increase in
the survival of T cells when analysing both JSLE patients
and controls together (n=9 pre treatment 25%+/-3.1;
rhBAFF treated, 19.7+/-2.7; p=0.008), and separately
(JSLE: pre treatment, 31.04%+/-2.34; rhBAFF treated,
25.03%+/-1.13, p=0.043; Control: pre-treatment, 17.59%
+/-4.27; rhBAFF treated, 12.99%+/-4.24, p=0.068). rhBAFF
also significantly down-regulated BAFF-R expression in
lymphocytes of both groups (n=9) Pre-treated; 11.51%
+/-2.00; rhBAFF treated: 5.02%+/-0.907) . Finally a positive
correlation with the disease activity score SLEDAI was
observed with JSLE patient BCMA receptor expression on
both lymphocytes (correlation coefficient r2=0.6 p=0.024)
and T cells (r2=0.67; p=0.013).
Conclusion
This study has demonstrated that T cells from paediatric
patients express BAFF receptors as previously noted in
adults. Interestingly both BAFF-R and BCMA receptors
were detected. Whether by direct signalling or an indirect
mechanism, BAFF has been shown to reduce apoptosis of
T cells in both JSLE patients and healthy controls. This
observation challenges the notion that T cells exclusively
express BAFF-R highlighting that BCMA expression on
T cells could be unique to the immature immune system.
Importantly, these data indicate that this ‘B cell survival
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factor’ is also capable of influencing the survival of T cells
in vitro. Aberrant T cell homeostasis is a pathogenic
feature of SLE. To understand how increased T cell survi-
val may affect the disease, it is important to understand
receptor expression on different T cell subsets, including
the inflammatory Th17 and anti-inflammatory Tregs.
Allowing a clearer picture of how BAFF inhibition may
affect the wider immune system.
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